CN115025070B - 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用 - Google Patents

一种快速自成膜抗感染镇痛喷剂及其制备方法和应用 Download PDF

Info

Publication number
CN115025070B
CN115025070B CN202210598862.3A CN202210598862A CN115025070B CN 115025070 B CN115025070 B CN 115025070B CN 202210598862 A CN202210598862 A CN 202210598862A CN 115025070 B CN115025070 B CN 115025070B
Authority
CN
China
Prior art keywords
film
spray
forming
self
infective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210598862.3A
Other languages
English (en)
Other versions
CN115025070A (zh
Inventor
高长有
王兆龙
董晓飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shaoxing Research Institute Of Zhejiang University
Zhejiang University ZJU
Original Assignee
Shaoxing Research Institute Of Zhejiang University
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaoxing Research Institute Of Zhejiang University, Zhejiang University ZJU filed Critical Shaoxing Research Institute Of Zhejiang University
Priority to CN202210598862.3A priority Critical patent/CN115025070B/zh
Publication of CN115025070A publication Critical patent/CN115025070A/zh
Application granted granted Critical
Publication of CN115025070B publication Critical patent/CN115025070B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种快速自成膜抗感染镇痛喷剂及其制备方法和应用。按重量计；所述喷剂的组成为：2‑10份复合成膜剂、4‑10份保湿剂、1‑10份表面活性剂、0.1‑5份超支化聚赖氨酸、0.1‑5份镇痛药物和10‑70份溶剂。本发明制得的液体喷剂在其中的有益成分作用下，可以加速溶剂挥发，具有快速自成膜特性，能在喷涂后3‑5秒内形成薄膜。成膜后具有一定的防水性、透气性、延展性，能够在创面表面形成一层保护膜，隔绝细菌感染，有效加速伤口愈合，减轻痛苦，在实际使用过程中只需适量喷涂在创面上，使用方便。

Description

一种快速自成膜抗感染镇痛喷剂及其制备方法和应用
技术领域
本发明涉及一种快速自成膜抗感染镇痛喷剂及其制备方法和应用，属于生物医药技术领域。
背景技术
随着皮肤创面二次污染的机会增加,继发感染也日益增多,从而加剧了清创的难度及抗生素的大量应用,不但给病人带来痛苦,也会延迟创面的愈合，并可能产生耐药性。对开放性创伤中预防感染是重要环节之一,传统的处理方法主要是用纱布包扎,常常受到外界水和细菌的污染。早期使用能够快速覆盖的创面预防感染的敷料,促进愈合是首选。
创面敷料可以覆盖伤口，提供抵御外部感染的临时屏障，并作为诱导模板，引导皮肤细胞重组以及随后宿主组织的浸润和整合，显示出对伤口愈合的显著效果。理想的皮肤创面敷料应满足以下要求：(1)良好的组织相容性，无毒性或炎症；(2)良好的保湿性，能维持创面湿润环境，促进细胞水合，对创面渗出物有一定的吸收；(3)有足够的物理机械强度，保证其完整性，避免材料破损引起的外来细菌入侵。
目前，市面上商业化的敷料主要包含：全透明敷料、泡沫敷料、水胶体敷料。传统敷料虽然经济实惠，但只能提供物理保护，并且往往还存在以下问题：1）不透气；2）很有可能会与一些伤口黏连；3）渗液较多时，要是没有立即拆换，很有可能会造成伤口周边肌肤预浸，造成二次感染。
液体敷料的出现和发展解决了上述问题，与传统敷料相比具有诸多优势：1）有利于溶解和中止坏死组织和纤维蛋白，并发挥自溶和清创的作用；2）有利于保持伤口相对恒定的温度和湿度，为伤口提供类似于身体内部环境的条件；3）可避免伤口与外界细菌接触，有效防止交叉感染。
但现有液体敷料技术中同样也存在许多问题：1）敷料在伤口处形成的膜强度不足。例如：纯丝素敷料（公开号：CN113293626A）强度不足，容易在人体运动过程中撕裂；丝素/聚已内酯纳米纤维膜的拉力虽远大于纯丝素膜，但丝素/聚已内酯纳米纤维膜抑菌效果差，且亲水性仍不能满足需求，导致丝素/聚已内酯纳米纤维膜的生物相容性差，易从创面表面脱落。2）成膜速度太慢。丝素/聚已内酯纳米纤维膜无法快速在伤口表面快速成膜。因此为解决上述现有液体敷料技术中存在的部分问题，现提供一种快速自成膜抗感染镇痛喷剂及其制备方法和应用。
发明内容
本发明的目的在于针对现有技术的不足，提供一种快速自成膜抗感染镇痛喷剂及其制备方法和应用。本发明通过将表面活性剂引入喷剂中，加快溶剂的挥发速度，从而能快速（在3-5秒内）在伤口处形成薄膜保护伤口。与其他液体敷料相比较，不但具有快速自成膜的特点，而且可以促进伤口愈合。对于急性创口的便捷处理，以及对于微创手术或者激光手术的术后恢复愈合等相关状况的修复都可以起到一定的促进作用。为了实现上述目的，本发明的技术方案为：
一种快速自成膜抗感染镇痛喷剂，按重量计：2-10份复合成膜剂、4-10份保湿剂、1-10份表面活性剂、0.1-5份超支化聚赖氨酸、0.1-5份镇痛药物和10-70份溶剂，所述喷剂能在喷涂后3-5秒内形成薄膜。
进一步的，所述的复合成膜剂为聚乙烯醇、聚乙烯吡咯烷酮、羟乙基纤维素、羧甲基纤维素钠、丙烯酸树脂中的任意至少两种组成。
进一步的，所述的表面活性剂为苯扎氯铵、苯扎溴铵、椰油基葡糖苷、月桂基葡糖苷、鲸蜡硬脂基葡糖苷、单硬脂酸甘油酯。
进一步的，所述的保湿剂为丙二醇、甘油、1，3-丁二醇、聚乙二醇、透明质酸中的任意一种。
进一步的，所述的溶剂为水、乙醇、异丙醇、正丁醇、六甲基二硅醚、正己烷、异辛烷、乙酸乙酯中的任意至少两种。
进一步的，所述的镇痛药物为吗啡、可待因、羟考酮、丁丙诺啡、曲马多、阿司匹林、扑热息痛(对乙酰氨基酚)、消炎痛(吲哚)、布洛芬(芬必得)、双氯芬酸钠、塞来昔布、美洛昔康、尼松胶囊、阿米替林、度洛西汀、卡马西平、普瑞巴林、加巴喷丁中的任意至少一种。
本发明的有益效果为：
本发明涉及一种具有快速自成膜、抗感染和镇痛功能的喷剂及其制备方法和应用，公开了具有快速自成膜功能的成膜剂组合物，为液体喷剂提供了一种功能组分选择。同时，本发明制备的喷剂采用表面活性剂加速溶剂挥发，在喷涂后3-5秒内迅速形成薄膜保护伤口，防止伤口二次损伤。此外，本发明公开的喷剂中添加的抗感染成分超支化聚赖氨酸可以与配方中的成分形成氢键增强膜的强度。最后，该喷剂中引入的镇痛药物，可以缓解因伤口带给患者的痛苦。本发明所提供一种快速自成膜抗感染镇痛喷剂，具有多种生物学性能，可以改善目前液体喷剂应用中的缺点。本发明工艺简单、效率高、重复性较好，所制备的液体喷剂不仅具有快速成膜，促进生长的潜能，而且具有良好的镇痛效果。
附图说明
图1为实施例1制得的液体喷剂实物图；
图2为实施例1制得的液体喷剂喷涂在表面5秒后成膜效果；
图3为实施例1制得的液体喷剂抗感染实验结果；
图4为对比例1制得的液体喷剂喷涂在表面30秒后成膜效果。
具体实施方式
下面结合附图和具体实施例对本发明方案做进一步的详细说明。所举实施例是为了更好地对本发明进行说明，但并不是本发明的内容仅局限于所举实施例。熟悉本领域的技术人员根据上述发明内容对实施方案进行非本质的改进和调整，仍属于本发明的保护范围。
实施例1
将100 mg聚乙烯醇和300 mg聚乙烯吡咯烷酮用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的所述超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将1 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂。将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂，将所述喷剂加入20mL的喷剂瓶。本实施例制备的喷剂展示图如图1所示，在表面喷涂一次，3秒后，在表面形成一层薄膜，其成膜效果如图2所示。将本方法制备的喷剂分别喷在大肠杆菌、金黄色葡萄球菌培养盘上，6小时后，喷剂对大肠杆菌、金黄色葡萄球菌的杀菌率达到100%，如图3所示抗感染实验结果。
实施例2
将100 mg羟乙基纤维素和300 mg羧甲基纤维素钠用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的所述超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将1 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂。将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂，将所述喷剂加入20mL的喷剂瓶。在表面喷涂一次，3秒后，在表面形成一层薄膜。与实施例1相比，改变成膜组分后同样可以达到快速成膜效果。
实施例3
将100 mg聚乙烯醇和300 mg聚乙烯吡咯烷酮用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的所述超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将0.5 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂。将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂，将所述喷剂加入20mL的喷剂瓶。在表面喷涂一次，5秒后，在表面形成一层薄膜。与实施例1相比，改变表面活性剂的量后依旧能达到预期的成膜时间。
对比例1
将100 mg聚乙烯醇和300 mg羟乙基纤维素加2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的所述超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的六甲基二硅醚：异辛烷加入所得的含有超支化聚赖氨酸的成膜剂中，充分混合，得所述的自成膜抗感染喷剂。将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得自成膜抗感染镇痛喷剂。将所述喷剂加入20mL的喷剂瓶中，在表面喷涂一次，3分钟后，在表面形成薄膜，其成膜效果如图4 所示。该对比例制得的喷剂中未加入表面活性剂，其虽也可自成膜，但是相比于实施例1可以看出，其成膜速度及效果均远不及实施例1结果。

Claims (4)

1. 一种快速自成膜抗感染镇痛喷剂的制备方法，其特征在于，将100 mg聚乙烯醇和300 mg聚乙烯吡咯烷酮用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将1 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂；将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂。
2. 一种快速自成膜抗感染镇痛喷剂的制备方法，其特征在于，将100 mg羟乙基纤维素和300 mg羧甲基纤维素钠用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将1 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂；将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂。
3. 一种快速自成膜抗感染镇痛喷剂的制备方法，其特征在于，将100 mg聚乙烯醇和300 mg聚乙烯吡咯烷酮用2 mL的乙醇溶解，得成膜剂预处理料；将5 mg的超支化聚赖氨酸添加到所得的成膜剂预处理料中，充分混合，得含有超支化聚赖氨酸的成膜剂；将10 mL体积比为1：1的异丙醇：乙醇加入所得的含有超支化聚赖氨酸的成膜剂中，并将0.5 mg苯扎氯铵加入充分混合，得含有超支化聚赖氨酸的自成膜抗感染喷剂；将100 μg阿司匹林加入含有超支化聚赖氨酸的自成膜抗感染喷剂，充分混合，得快速自成膜抗感染镇痛喷剂。
4.一种快速自成膜抗感染镇痛喷剂，其特征在于，采用如权利要求1-3任一项所述的方法制得。
CN202210598862.3A 2022-05-30 2022-05-30 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用 Active CN115025070B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210598862.3A CN115025070B (zh) 2022-05-30 2022-05-30 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210598862.3A CN115025070B (zh) 2022-05-30 2022-05-30 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115025070A CN115025070A (zh) 2022-09-09
CN115025070B true CN115025070B (zh) 2024-02-09

Family

ID=83120149

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210598862.3A Active CN115025070B (zh) 2022-05-30 2022-05-30 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN115025070B (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008225B1 (ko) * 1993-04-07 1996-06-20 최수부 의약품의 신규 필름제형 및 그 제조방법
CN105903056A (zh) * 2016-06-02 2016-08-31 四川奎星医用高分子制品有限责任公司 含有镇痛药物的医用复合海藻酸盐敷料及其制备方法
CN112156224A (zh) * 2020-01-20 2021-01-01 海南海默斯医学生物科技有限公司 用于制备角蛋白液体敷料的组合物及其制备方法和应用
CN113577377A (zh) * 2021-08-17 2021-11-02 浙江大学 一种活性氧消除抗菌消炎水凝胶皮肤敷料及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101457789B1 (ko) * 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960008225B1 (ko) * 1993-04-07 1996-06-20 최수부 의약품의 신규 필름제형 및 그 제조방법
CN105903056A (zh) * 2016-06-02 2016-08-31 四川奎星医用高分子制品有限责任公司 含有镇痛药物的医用复合海藻酸盐敷料及其制备方法
CN112156224A (zh) * 2020-01-20 2021-01-01 海南海默斯医学生物科技有限公司 用于制备角蛋白液体敷料的组合物及其制备方法和应用
CN113577377A (zh) * 2021-08-17 2021-11-02 浙江大学 一种活性氧消除抗菌消炎水凝胶皮肤敷料及其制备方法

Also Published As

Publication number Publication date
CN115025070A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
WO2019091150A1 (zh) 一种藻酸盐创面修复敷料及其制备方法
CN105778126B (zh) 一种京尼平交联生物凝胶及其制备方法与应用
TWI401098B (zh) 傷口敷料
CN105903068A (zh) 含有镇痛药物的医用复合壳聚糖凝胶
CN112826975B (zh) 一种医用壳聚糖快速止血敷料及制备方法
JP2017213376A (ja) 組織ドレッシングキット
CN107185031B (zh) 一种具有生物活性的医用敷料及其制备方法
CN115124738B (zh) 一种双层仿生载药水凝胶及其制备与应用
KR20070080823A (ko) 활성약물 함유 상처 치료용 하이드로겔 제제
CN110585474B (zh) 海洋生物多糖基复合海绵的制备方法、复合海绵及应用
US20150314114A1 (en) Collagen device
CN108066814A (zh) 一种细菌纤维素抗菌敷料的制备方法
CN110859989B (zh) 一种液体创可贴及其制备方法
CN104740141B (zh) 一种抗菌喷剂及其制备方法
CN110876814A (zh) 一种富含抗菌肽的液体创可贴及其制备方法
CN112843220B (zh) 一种用于抑制疤痕生成的反蛋白石膜及其制备方法
RU2699362C2 (ru) Композиция на основе наночастиц диоксида церия и полисахаридов бурых водорослей для лечения ран
CN115025070B (zh) 一种快速自成膜抗感染镇痛喷剂及其制备方法和应用
CN109432483B (zh) 一种加速创面愈合的医用敷料及其制备方法和应用
CN110898038A (zh) 一种鲨鱼肽凝胶涂膜剂及其制备方法
CN108452370A (zh) 一种复合型超分子水凝胶及其制备方法
EP3656404A1 (en) Film for topical use for treating skin lesions and method for producing and applying same
CN113616849A (zh) 一种用于外部伤口护理的液体敷料及其制备方法
CN103394118B (zh) 微纳仿生结构缓释型敷料的制备方法
Sun et al. A nanofiber hydrogel derived entirely from ocean biomass for wound healing

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant